Compare Inovio Pharmaceuticals Inc (INO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: IQIYI Inc - ADR is far larger — about 8.7× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and IQIYI Inc - ADR for 55 Days on average.
| INO | IQ | |
|---|---|---|
Market Cap | $112.19M | $974.67M |
Volume | 3,201,278 | 4,964,108 |
Sector | Health | Media |
52-Week High | $2.65 | $2.35 |
52-Week Low | $0.66 | $0.86 |
Typical Hold Time | 43 Days | 55 Days |
Enterprise Value | $83.51M | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
iQIYI (IQ) trades at $1.01, down 0.49% with bearish technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million for 2025. Analyst consensus is mixed with 50% buy ratings, while technical indicators show bearish momentum with neutral oscillators. Recent developments include the successful launch of AI-generated content series 'The Ferry Man' generating over RMB 8 million in revenue-sharing.
The outlook remains challenging with declining revenue trends and negative profitability, though the company's pivot to AI-driven content production offers potential cost savings. Key risks include streaming business contraction and Chinese regulatory environment. Wall Street maintains cautious optimism with 11 buy ratings but investors should monitor Q3 earnings for turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
